Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 9;7(32):50828-50834.
doi: 10.18632/oncotarget.10341.

Virtual screening, optimization, and identification of a novel specific PTP-MEG2 Inhibitor with potential therapy for T2DM

Meiyan Wang  1 , Xiaobo Li  1   2 , Lei Dong  2 , Xiubo Chen  3 , Weiren Xu  4 , Runling Wang  1
Affiliations

Virtual screening, optimization, and identification of a novel specific PTP-MEG2 Inhibitor with potential therapy for T2DM

Meiyan Wang et al. Oncotarget. .

Abstract

Megakaryocyte protein tyrosine phosphatase 2 (PTP-MEG2) is a tyrosine phosphatase expressed in megakaryocytic cells, and causes insulin sensitization when down regulated. Therefore, specific inhibitors of PTP-MEG2 are potential candidates for novel Type 2 Diabetes (T2DM)therapy. In this study, we discovered PTP-MEG2 inhibitors using high throughput and virtual screening (HTS/VS) and structural optimization in silicon.Eight compound-candidates were identified from the interactions with PTP-MEG2, protein tyrosine phosphatase 1B (PTP1B) and T cell protein tyrosine phosphatase (TCPTP). Results from enzymatic assays show compounds 4a and 4b inhibited PTP-MEG2 activity with an IC50 of 3.2 μM and 4.3 μM, respectively. Further, they showed a 7.5 and 5.5 fold change against PTP1B and TCPTP, respectively. We propose compounds 4a and 4b are PTP-MEG2 inhibitors with potential therapeutic use in T2DM treatment.

Keywords: Gerotarget; PTP-MEG2 inhibitor; core hopping; diabetes; molecular dynamics simulation; selectivity.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTERESTS The Authors do not have any conflicts of interest.

Figures

Figure 1
Figure 1. ZINC01433265 derivatives with high docking scores generated by core hopping
Figure 2
Figure 2. Synthetic routes of compounds 4a and 4b
Figure 3
Figure 3. Docking of compound 4a with PTP-MEG2
a. Surface representation of PTP-MEG2 in complex with 4a. b. Docking interactions of compound 4a with PTP-MEG2 active site. The H-bond interactions between PTP-MEG2 and compound 4a are shown as red dashed lines.
Figure 4
Figure 4. The interaction energies of top 10 pairwise residues of the complex formed by PTP-MEG2 (red), PTP1B (blue), and TCPTP (purple) with compound 4a
See this image and copyright information in PMC

References

    1. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995;80(2):225–236. - PubMed
    1. Li XB, Wang SQ, Xu WR, Wang RL, Chou KC. Novel inhibitor design for hemagglutinin against H1N1 influenza virus by core hopping method. PloS one. 2011;6(11):e28111. - PMC - PubMed
    1. Tonks NK, Neel BG. Combinatorial control of the specificity of protein tyrosine phosphatases. Current opinion in cell biology. 2001;13(2):182–195. - PubMed
    1. Zhang ZY. Protein tyrosine phosphatases: prospects for therapeutics. Current opinion in chemical biology. 2001;5(4):416–423. - PubMed
    1. Aravind L, Neuwald AF, Ponting CP. Sec14p-like domains in NF1 and Dbl-like proteins indicate lipid regulation of Ras and Rho signaling. Curr Biol. 1999;9(6):R195–197. - PubMed

MeSH terms

Substances